Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of palbociclib when given together
with dexamethasone in treating participants with B-cell acute lymphoblastic leukemia that has
come back after a period of improvement or does not respond to treatment. Palbociclib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Dexamethasone is a steroid medication that is used in combination with other medications to
treat B-cell acute lymphoblastic leukemia. Giving palbociclib together with dexamethasone may
work better in treating patients with B-cell acute lymphoblastic leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University